ArticleIntestinal research2025

A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease.

Kwang Woo Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.